Home > PE Ratio > MANKIND PHARMA

MANKIND PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of MANKIND PHARMA is 50.85.

Share Price ₹2,371.8Jun 10,2026
Market Cap ₹97,953.3 Cr
Earnings-TTM₹1,926.4 CrTTM-Consolidated Results
Price/Earnings50.85xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results
MANKIND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of MANKIND PHARMA is calculated as :

Current Market Cap [ ₹97,953.3 Cr] as on Jun 10,2026

(/) Earnings [ ₹1,926.4 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 50.85x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for MANKIND PHARMA , the investors are currently willing to pay 50.85 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA


PE Ratio Performance Analysis for MANKIND PHARMA

- MANKIND PHARMA 's latest p/e ratio is 50.85x.

- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.67x.

- MANKIND PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.

- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.


How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
MANKIND PHARMA 1,926.4150.8597,953.3
SUN PHARMACEUTICAL INDUSTRIES LTD11,564.5037.08428,785.0
DIVIS LABORATORIES LTD2,568.0068.63176,242.0
TORRENT PHARMACEUTICALS LTD2,138.0070.65151,058.0
CIPLA LTD3,869.7928.73111,180.0
DR REDDYS LABORATORIES LTD4,144.2025.61106,149.0
LUPIN LTD5,355.4719.20102,818.0
ZYDUS LIFESCIENCES LTD5,026.4021.98110,474.0
AUROBINDO PHARMA LTD3,501.4523.8983,654.2
LAURUS LABS LTD889.8584.0974,827.3
BIOCON LTD368.80181.9867,113.7

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 19.20x
Max industry PE 181.98x
Median industry PE 37.08x
Average industry PE 55.70x



You may also like the below Video Courses